Journal Article10.1016/S0140-6736(09)61497-5
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
Tudor Ciuleanu,Thomas Brodowicz,Christoph C. Zielinski,Joo Hang Kim,Maciej Krzakowski,E. Laack,Yi-Long Wu,Isabel Bover,Stephen Begbie,Valentina Tzekova,Branka Cucevic,José Rodrigues Pereira,Sung Hyun Yang,Jayaprakash Madhavan,Katherine P. Sugarman,Patrick Peterson,William J. John,K. Krejcy,Chandra P. Belani +18 more
TL;DR: Maintenance therapy with pemetrexed is well tolerated and offers improved progression-free and overall survival compared with placebo in patients with advanced non-small-cell lung cancer.
read more
About: This article is published in The Lancet. The article was published on 24 Oct 2009. The article focuses on the topics: Pemetrexed & Survival rate.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer:
Martin Metzenmacher,Hans-Georg Kopp,Frank Griesinger,Niels Reinmuth,Martin Sebastian,Monika Serke,Cornelius F. Waller,Michael Thomas,Jochen Eggert,Gerald Schmid-Bindert,Mathias Hoiczyk,Daniel C. Christoph,M Kimmich,Burkhard Deuß,Stephanie Seifert,Swantje Held,Martin Schuler,Thomas Herold,Frank Breitenbuecher,Wilfried Eberhardt +19 more
TL;DR: Advantages of split-dose cisplatin with regard to specific toxicities allow personalization of this important chemotherapy backbone and safe and effective, and global health status, fatigue and constipation demonstrated superior scores in B.
3
Maintenance therapy for patients with advanced non-small cell lung cancer: Who to treat and how to treat?
TL;DR: An overview on the current evidence and personal recommendations for clinical practice are given, especially in the light of efficacious and better tolerable drugs and the results of recent clinical trials.
3
Pemetrexed as the first-line therapy for Chinese patients with advanced non-squamous non-small-cell lung cancer.
TL;DR: Wang et al. as mentioned in this paper analyzed the outcome in 75 Chinese non-squamous NSCLC patients treated with pemetrexed as first-line therapy and assessed its efficacy and tolerability.
3
Current treatment concepts of lung cancer
TL;DR: The prognosis in the metastasised stage is unfavourable with a 5-year overall survival rate of 6% for small cell lung cancer (SCLC) and 18% for non-small cell lung Cancer (NSCLC).
3
Patent
Method for classifying tumour cells
Jun Hou,Joan Geertrudis Jacobus Victor Aerts,Franklin Gerardus Grosveld +2 more
- 30 Nov 2012
TL;DR: In this paper, a method for preparing an optimised gene signature for assigning a NSCLC sample to one or more classes, comprising subjecting a gene signature set forth in Table 12 herein to nearest shrunken centroid analysis, was presented.
3
References
Global cancer statistics
TL;DR: A substantial proportion of the worldwide burden of cancer could be prevented through the application of existing cancer control knowledge and by implementing programs for tobacco control, vaccination, and early detection and treatment, as well as public health campaigns promoting physical activity and a healthier dietary intake.
•Book
AJCC Cancer Staging Manual
Mahul B. Amin,Stephen B. Edge,Frederick L. Greene,David R. Byrd,Robert K. Brookland,Mary Kay Washington,Jeffrey E. Gershenwald,Carolyn C. Compton,Kenneth R. Hess,Daniel C. Sullivan,J. Milburn Jessup,James D. Brierley,Lauri E. Gaspar,Richard L. Schilsky,Charles M. Balch,David P. Winchester,Elliot A. Asare,Martin Madera,Donna M. Gress,Laura R. Meyer +19 more
- 17 Sep 2013
TL;DR: Purposes and Principles of Cancer Staging and End-Results Reporting are explained.
20.9K
Global cancer statistics, 2002.
TL;DR: There are striking variations in the risk of different cancers by geographic area, most of the international variation is due to exposure to known or suspected risk factors related to lifestyle or environment, and provides a clear challenge to prevention.
20.2K
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Patrick Therasse,Susan G. Arbuck,Elizabeth Eisenhauer,Jantien Wanders,Richard Kaplan,Larry Rubinstein,Jaap Verweij,Martine Van Glabbeke,Allan T. van Oosterom,Michaele C. Christian,S. Gwyther +10 more
TL;DR: A model by which a combined assessment of all existing lesions, characterized by target lesions and nontarget lesions, is used to extrapolate an overall response to treatment is proposed, which is largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines.
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan B. Sandler,Robert Gray,Michael C. Perry,Julie R. Brahmer,Joan H. Schiller,Afshin Dowlati,Rogerio Lilenbaum,David H. Johnson +7 more
TL;DR: The addition of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non-small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths.
Related Papers (5)
Giorgio V. Scagliotti,Purvish M. Parikh,Joachim von Pawel,Bonne Biesma,Johan Vansteenkiste,Christian Manegold,Piotr Serwatowski,Ulrich Gatzemeier,Raghunadharao Digumarti,Mauro Zukin,Jin S. Lee,Anders Mellemgaard,Keunchil Park,Shehkar Patil,Janusz Rolski,Tuncay Göksel,Filippo de Marinis,Lorinda Simms,Katherine P. Sugarman,David R. Gandara +19 more
Nasser H. Hanna,Frances A. Shepherd,Frank V. Fossella,José Rodrigues Pereira,Filippo de Marinis,Joachim von Pawel,Ulrich Gatzemeier,Thomas Chang Yao Tsao,Miklos Pless,Thomas Müller,Hong-Liang Lim,Christopher Desch,Klara Szondy,Radj Gervais,Shaharyar,Christian Manegold,Sofia Paul,Paolo Paoletti,Lawrence H. Einhorn,Paul A. Bunn +19 more
Tony Mok,Yi-Long Wu,Sumitra Thongprasert,Chih-Hsin Yang,Da Tong Chu,Nagahiro Saijo,Patrapim Sunpaweravong,Baohui Han,Benjamin Margono,Benjamin Margono,Yukito Ichinose,Yutaka Nishiwaki,Yuichiro Ohe,Jin Ji Yang,Busyamas Chewaskulyong,Haiyi Jiang,Emma Duffield,Claire Watkins,Alison Armour,Masahiro Fukuoka +19 more
Frances A. Shepherd,José Rodrigues Pereira,Tudor Ciuleanu,Eng Huat Tan,Vera Hirsh,Sumitra Thongprasert,Daniel Campos,Savitree Maoleekoonpiroj,Michael Smylie,Renato G. Martins,Maximiliano Van Kooten,Mircea Dediu,B. Findlay,Dongsheng Tu,Dianne Johnston,Andrea Bezjak,Gary M. Clark,Pedro Santabárbara,Lesley Seymour +18 more